HomeMy WebLinkAboutFully Executed DocumentDocusign Envelope lD: 97E7029C-8CD5-4FBF-9DC4-1 837DD2691 89
PRIOR MAXIMUM CONTRACT AMOUNT
$1,017,775
AMENDMENT START DATE
July 1 ,2025
CONTRACTOR ADDRESS
205 W. 5th Avenue, Suite #1
Ellensburg, WA 98926
CONTRACTOR NAME
Kittitas County
THIS AMENDMENT TO THE CONTRACT is between the Washington State Health Care Authority and the party
whose name appears below, and is effective as of the date set forth below
Washington State
Health Care thority
AMOUNT OF INCREASE
$209,000
CONTRACT
AMENDMENT
CONTRAGT END DATE
June 30, 2026
CONTRACTOR CONTRACT MANAGER
Name: Edward Buntin
Email: edward. buntin@co. kittitas.wa. us
CONTRACTOR doing business as (DBA)
Kittitas County Sheriff-Jail
TOTAL MAXIMUM COMPENSATION
$1,226,775
HCA Contract No.: K5885
Amendment No.: 04
WHEREAS, HCA and Contractor entered into Contract K5885 for to develop and implement, or
expand, the Medication for Opioid Use Disorder (MOUD) and Medications for Alcohol Use Disorder
(MAUD) in Jails program, and;
WHEREAS, HCA and Contractor wish to amend the Contract pursuant to Section 4.3, Amendments,
to extend the Contract term, increase funding, and incorporate a revised and restated Statement of
Work;
THEREFORE, the parties agree the Contract is amended as follows:
1. Section 2, Definitions, two (2) new, defined terms are added, and incorporated in alphabetical
order, as follows:
"Medications for Alcohol Use Disorder" or "MAUD" means a medical treatment approach that
uses FDA-approved medications to help individuals with Alcohol Use Disorder (AUD) reduce or
stop their opioid use and improve their overall health and well-being.
"Medications for Opioid Use Disorder" or "MOUD" means a medicaltreatment approach
that uses FDA-approved medications to help individuals with Opioid Use Disorder (OUD)
reduce or stop their opioid use and improve their overall health and well-being.
2. Section 3.2, Term, subsection 3.2.1, is amended to extend the Contract term as follows:
3.2.1 The initial term of the Contract will commence on March 1,2022, and continue through
June 30, 2026, unless terminated sooner as provided herein.
3. Section 3.3, Compensation, subsection 3.3.1 is amended to reflect the $209,000 increase in
funding, the maximum compensation is as follows:
3.3.1 The parties have determined the cost of accomplishing the work herein will not exceed
$1,226,775, inclusive of all fees, taxes, and expenses. Compensation for satisfactory
performance of the work will not exceed this amount unless the parties agree to a
higher amount through an amendment.
RECEIVED
ocT I 7 2A25
KITTITS,S COU}+TY
EOARD 0F $CMFEi!SS!OF|ERS
HCA Contract No. K5885-04 Page 1 of 13
Docusign Envelope lD: 97E7029C-8CD5-4FBF-9DC4-1 837DD2691 89
4. Section 3.4, lnvoice and Paymenf is revised to make minor updates and incorporate additional
detail regarding cost reimbursement payment requirements. Section 3.4, lnvoice and
Payment, now reads as follows:
3.4 INVOICE AND PAYMENT
3.4.1
3.4.2
3.4.3
3.4.4
ln order to receive payment for services or products provided to a state agency,
Contractor must register with the Statewide Payee Desk at https://ofm.wa.qov/it-
svstems/statewide-vendorpavee-services/receivi nq-pavment-state.
lnvoices must describe and document to the HCA Contract Manager's
satisfaction a description of the work performed, the progress of the project, and
fees. All invoices and deliverables will be approved by the HCA Contract
Manager prior to payment. Approvalwill not be unreasonably withheld or delayed
lf expenses are invoiced, invoices must provide a detailed breakdown of each
type. Expenses of $50 or more must be accompanied by a receipt.
lnvoices must be submitted using the A-19 lnvoice Voucher form to
rachel.meade@hca.wa.qov with the_HCA Contract number in the subject line of
the email. lnvoices must include the following information, as applicable:
a. The HCA Contract number;
b. Contractor name, address, phone number;
c. Description of services;
d. Date(s) of delivery;
e. Net invoice price for each item;
f. Applicable taxes;
g. Total invoice price; and
h. Any available prompt payment discount.
3.4.5 HCA will return incorrect or incomplete invoices for correction and reissue.
Payment will be considered timely if made within thirty (30) calendar days of
receipt of properly completed invoices.
3.4.6 Upon expiration of the Contract, any claims for payment for costs due and
payable under this Contract that are incurred prior to the expiration date must be
submitted by the Contractor to HCA within sixty (60) calendar days after the
Contract expiration date. HCA is under no obligation to pay any claims that are
submitted sixty-one (61) or more calendar days after the Contract expiration date
("Belated Claims"). HCA will pay Belated Claims at its sole discretion, and any
such potential payment is contingent upon the availability of funds.
5. Section 3.7, lncorporation of Documents and Order of Precedence, is amended to reflect the
changes made with this amendment and now reads as follows:
3.7 INCORPORATION OF DOCUMENTS AND ORDER OF PRECEDENCE
Each of the documents listed below is by this reference incorporated into this Contract.
ln the event of an inconsistency, the inconsistency will be resolved in the following
order of precedence:
HCA Contract No. K5885-04 Page 2 of 13
Docusign Envelope lD: 97E7029C-8CD5-4FBF-9DC4-1 837DD2691 89
3.7.1
3.7.2
3.7.3
3.7.4
3.7.5
3.7.6
3.7.7
3.7.8
Applicable Federal and State of Washington statutes and Regulations;
Recitals;
Special Terms and Conditions;
General Terms and Conditions;
Schedule A(s): Statement(s) of Work;
Exhibit A: HCA RFA 2021HCA42;
Exhibit B: Contractor Response to HCA RFA 2021HCA42; and;
Any other provision, term or material incorporated herein by reference or
otherwise incorporated.
6. This Amendment corrects an error, Attachment 1, Data Use Security and Confidentiality, and
related Attachments 2, 3, and 4 were unnecessarily included and are now removed in their
entirety. All references related toAttachments 1,2,3, and 4,are also removed.
7. A new Schedule A-4; Statement of Work, is added to prevent redundancy between the
previous Schedule A(s), Sfafement(s) of Work, while also incorporating updates. ln the event
of an inconsistency the revised and restated Schedule A-4, Statement of Work, shall
supersede all previous Schedule A(s), Sfafement(s) of Work.
The revised and restated Schedule A-4, Statement of Work, is attached hereto and by this
reference is incorporated into the Contract.
8. A new Attachment 1, MOIJD & MAUD in Jails Program Monthly Progress Report, is added for
Contractor's use in meeting the requirements of Schedule A-4; Statement of Work, Section 3,
Reporting. The new Attachment 1, MOUD & MAUD in Jails Program Monthly Progress Report,
is attached hereto and by this reference is incorporated into the Contract.
9. A new Attachment 2, MOUD Monthly Data Collection Spreadsheef, is added for Contractor's
use in meeting the requirements of Schedule A-4; Statement of Work, Sedion 3, Reporting.
The new Attachment 2, MOUD Monthly Data Collection Spreadsheet, is by this reference
incorporated into the Contract.
10. This Amendment is effective July 1 , 2025, ("Effective Date").
11. All capitalized terms not otherwise defined herein have the meaning ascribed to them in the
Contract.
12. All other terms and conditions of the Contract remain unchanged and in full force and effect.
The parties signing below warrant that they have read and understand this Amendment and have authority to
execute the Amendment. This Amendment will be binding on HCA only upon signature by both parties.
HCA-SIGNATURE
-sEneq
Dy:
l^:,,e"ltv Sdil]fu^La]ut
CONTRACTOR
-Signed
bY:
SIGNATURE
@\*
PRINTED
Annette
NAME AND TITLE
Schuffenhauer
Chief Legal Officer
PRINTED NAME AND TITLT
Clay Myers
Sheriff
DATE SIGNED
10t1612025
DATE SIGNED
10t16t2025
HCA Contract No. K5885-04 Page 3 of 13
Docusign Envelope lD: 97E7029C-8CD5-4FBF-9DC4-1 837DD2691 89
SCHEDULE A-4
Statement of Work
July 1, 2025 - June 30, 2026
1. PURPOSE
Support a comprehensive treatment program for incarcerated individuals with Opioid Use Disorder
(OUD) and Alcohol Use Disorder (AUD), beginning with screening upon entry and ending with
seamless transition to the care in the community, with use of Medications for Opioid Use Disorder
(MOUD) and Medications for Alcohol Use Disorder (MAUD) at its core.
This Contract supports RCW 71.24.599: Opioid use disorder-Citv and countv iails-Fundinq.
(wa.qov).
Health Equity - This program also intends to address inequities in treatment and recovery services
by providing medically necessary treatment to incarcerated individuals. Programs should
understand cultural barriers and provide culturally appropriate services. Additionally, this program
intends to identify stigma and educate to ensure ongoing collaboration and openness to change.
2. WORK EXPECTATIONS
Contractor shall ensure funds are responsibly used towards the Opioid Use Disorder (OUD) and
Alcohol Use Disorder (AUD) treatment programs in the jail and provide the community standard of
care, including, at a minimum, the following core components:
2.1. General Standard of Gare
2.1.1. 2020 ASAM National Practice Guideline for the Treatment of Opioid Use Disorder.
2.1.2. Guidelines for Manaqinq Substance Withdrawal in Jails;
2.1.3. For American lndian/Alaska Native (A|/AN) individuals receiving Medications for
Opioid Use Disorder (MOUD) and/or Medications for Alcohol Use Disorder (MAUD)
services, Contractor, shall coordinate with the individual's lndian Health Care
Provider (IHCP) to ensure the IHCP can participate in treatment and discharge
planning, including continuity of care in the nearest IHCP clinically appropriate
setting for all AI/AN individuals participating in the program.
2.2. lntake
2.2.1.Screen all newly admitted individuals for risk of acute withdrawal from opioids and
alcohol upon intake.
MOUD, MAUD, and other medications which support the relief of withdrawal
symptoms, such as clonidine, anti-emetics, anti-diarrheals, and analgesics must be
offered to individuals at no charge to the individual.
Offer initiation of MOUD treatment to individuals who are physically dependent on
opioids, may have withdrawal symptoms or have disclosed recent use and
anticipate withdrawal.
Offer treatment for withdrawal with benzodiazepines to individuals entering the
facility who are physically dependent on alcohol, if clinically appropriate.
2.2.2
2.2.3
2.2.4.
HCA Contract No. K5885-04 Page 4 of 13
Docusign Envelope lD: 97E7029C-8CD5-4FBF-9DC4-1837DD269189
2.2.5.
2.2.6.
2.2.7
2.2.8
2.2.9
Continue MOUD and MAUD for individuals who are already taking these
medications upon entering the facility.
Continue the individual on the same medication at the same dose unless ordered
otherwise by the prescriber based on clinical need, and as documented in the
individual's medical record, unless one of the following exceptions is applicable:
2.2.6.1. lnjectable long-acting naltrexone may be converted to an equivalent oral
dose untiljust prior to release at which time the injectable form shall be
restarted.
2.2.6.2.lnjectable long-acting buprenorphine may be converted to an equivalent
oral dose until just prior to release at which time the injectable form shall
be restarted.
2.2.6.3 Oral buprenorphine may be converted to any of the three formulations
available; film, tablet with naloxone, or tablet without naloxone.
2.2.6.4 lf the individual is not pregnant, methadone may be transitioned to
buprenorphine if the Contractor is not a licensed Opioid Treatment
Program (OTP) and the nearest OTP is not within reasonable driving
distance from the jail or there is no OTP within reasonable distance of
the individual's release residence.
2.2.6.5.Though MOUD/MAUD may not be discontinued on a policy or
administrative basis because of the presence of other illicit or controlled
substances, administration of the community-based MOUD or MAUD
may be adjusted if clinically necessary due to pharmacologic risks of
d rug-to-drug interaction.
Screen for OUD and AUD without physical dependence (i.e. without a risk of acute
withdrawal) after intake, as long as the delay does not impair the ability to begin
treatment prior to release.
Educate individuals on treatment choices and the process for continuation of
access to MOUD during incarceration and upon release.
Make available and offer treatment using some formulation of methadone,
buprenorphine, and naltrexone based on a mutually agreed-upon plan between the
prescriber and the individual, with the following exceptions or caveats:
2.2.9.1. The Contractor may decline to offer methadone if the Contractor is not a
licensed OTP, and the nearest OTP is not within reasonable driving
distance from the jail or there is no OTP within reasonable distance of
the individual's release residence.
2.2.9.2 lf there is no available buprenorphine provider in the community to
which the individualwill release, the Contractor must still offer
buprenorphine (tapered over several days) if opioid withdrawal is
clinically indicated.
HCA Contract No. K5885-04 Page5of13
Docusign Envelope lD: 97E7029C-8CD5-4FBF-9DC4-1 837DD2691 89
2.2.9.3.lf withdrawal is not clinically indicated and the only reason for
considering discontinuation of buprenorphine is the lack of an available
buprenorphine provider in the community to which the individual will be
released, the decisions when or if buprenorphine should be
discontinued prior to release should be made based on the following:
a. A plan mutually agreed-upon between the individual and the
prescriber;
b. The length of time the individual is expected to remain in the jail;
c. The risks of opioid misuse or overdose during the incarceration; and
d. The individual's willingness to receive a dose of an extended-release
injectable buprenorphine just prior to release which will provide a
safe tapered withdrawalfor the individual.
2.2.9.4 Provide naltrexone in oralformulation while the individual is
incarcerated. Offer injectable long-acting naltrexone or buprenorphine
as an option prior to release.
2.2.9.5 Offer oral buprenorphine without naloxone while the individual is
incarcerated but must discharge the individual on a formulation of
buprenorphine with naloxone unless there is a clinical reason not to do
so. E.g., the individual is discharged on injectable buprenorphine, the
individual is allergic to naloxone.
2.2.10 Contractor shall not facilitate forced opioid withdrawal, including withdrawal using a
tapering dose of buprenorphine or methadone, unless the individual provides an
informed refusal of treatment or the individual elects MOUD treatment with
naltrexone, in which case withdrawal is clinically required.
2.2.10.1. ln such case, Contractor may use other medications (e.9., clonidine,
anti-emetics, anti-diarrheals, analgesics, etc.) in place of buprenorphine
or methadone if the individual chooses or as adjuncts to these
medications, but they may not be the only withdrawaltreatment
available.
2.2.10.2 lnitiation of buprenorphine or methadone, whether for induction of
treatment or for withdrawal, may not be delayed for administrative
reasons, e.9., unavailability of a prescriber, beyond when they are
clinically indicated to be started.
2.2.11. Provide immediate evaluation to individuals at risk for, or in, opioid or alcohol
withdrawalwho refuse treatment by a medical or mental health prescriber or a
licensed mental health professional at the masters' level or higher, to determine if
they have decision-making capacity.
HCA Contract No. K5885-04 Page 6 of 13
Docusign Envelope lD: 97E7029C-8CD5-4FBF-9DC4-1 837DD2691 89
2.2.11.1 lf they do not, they must be transpoded to a community hospital and
may not return to the jail until they are clinically safe to return to the jails
AND have regained decision-making capacity.
2.3. During lncarceration
2.3.1. Offer initiation of MOUD/MAUD to individuals with unidentified OUD/AUD and/or if
treatment was not offered at intake. E.9., individuals with OUD but without physical
dependence, individuals with AUD who underwent withdrawal, etc.
2.3.2. Educate individuals on treatment choices and the process for continuation of
access to MOUD/MAUD during incarceration and upon release.
2.3.3. Administer methadone and buprenorphine daily or more frequently.
2.3.4. Contractor shall not use alternate-day or "balloon" dosing of buprenorphine.
2.3.5. Offer counseling to individuals for their OUD/AUD if they are expected to remain in
jail for longer than one month.
2.3.6. Provide MOUD/MAUD regardless of the individual's willingness to participate in
counseling.
2.4. Release
Contractor must accomplish the following prior to each individual's release from jail:
2.4.1. Complete release planning and reentry coordination as soon as possible after
admission to ensure an effective plan is in place prior to release or in the event of
an unexpected release of an individual who needs continued treatment and
services.
2.4.2. Provide at least two (2) doses of naloxone (e.9., Narcan@) and training on how to
administer the medication to all individuals with OUD.
2.4.3. Schedule the first community appointment with a treatment facility for continuation
of MOUD Or MAUD.
2.4.4. Provide in hand, upon release, and at no cost to the individual, sufficient doses of
MOUD and/or MAUD to bridge, or sustain treatment for, the individual until the
scheduled MOUD/MAUD follow-up appointment at the selected community
treatment facility. This does not apply to individuals treated with injectable
MOUD/MAUD.
2.4.4.1. lf an individual is at risk of being released directly from court, inform
them prior to going to court that they may request to be transported
back to the jail by staff to receive these medications prior to going home
2.4.4.2 ln situations where a follow-up appointment upon release cannot be
made, e.9., after-hours bail-out, give the individual enough medication to
last untilthe next available appointment at the community treatment
facility. lf the appointment date is unknown, give the individual a 30-day
supply at minimum.
HCA Contract No. K5885-04 Page 7 of 13
Docusign Envelope lD: 97E7029C-8CD5-4FBF-9DC4-1 837DD269't 89
2.4.4.3.ln situations where medications cannot be provided upon release, e.9.,
unscheduled release at a time when medical staff are not present in jail,
Contractor must ensure the following:
a. The individual is informed that they may either return to the jail in the
morning to receive bridge medications; or
b. lf no medical staff are present the following day, call in a prescription
for the same bridging medication to a local pharmacy, at no cost to
the individual.
2.4.5.Assist Medicaid-eligible individuals to sign up for Medicaid, or assist individuals
whose Medicaid coverage has been terminated to reestablish coverage.
For any individualwith Medicaid coverage, work cooperatively with the individual's
Managed Care Organizations (MCO) to facilitate re-entry benefits and continued
treatment with a community partner, including but not limited to allowing the MCO's
agent timely access to the jail and the individual.
2.4.6
2.5. Contract Management
2.5.1. Ensure operation specific tools, such as job descriptions, policies and procedures,
and statements of work, are developed, and staff are adequately trained, to ensure
consistent and appropriate practice.
2.5.2. Attend monthly meetings with HCA Contract Manager to discuss Contract
requirements, compliance, and problem-solving. Attend additional meetings as
required or deemed necessary by the HCA Contract Manager.
2.5.3. Contractor shall cooperate with periodic site visits by the HCA DBHR program
administrator or designee and make all relevant records and personnel available.
3. REPORTING
Contractor shall complete performance monitoring activities, including the submission of timely
and accurate data reports to the HCA Contract Manager, utilizing the HCA provided templates.
Further evaluation, including on- and off-site data collection may be conducted by HCA or an
HCA-designated third party. Reporting shall include, but is not limited to, the following:
3.1. Monthly Progress Reports
3.1 .1. Due no later than the 10h day of the month following the month in which the
services being reported were provided.
3.1.2. See Attachmenll, MOUD & MAUD in Jails Program Monthly Progress Report.
3.2. Monthly Data Collection Spreadsheet
3.2.1. Due no later than the 1Oft day of the month following the month in which the
services being reported were provided.
3.2.2. See Attachment2, MOUD Monthly Data Collection Spreadsheet.
HCA Contract No. K5885-04 Page8of13
Docusign Envelope lD: 97E7029C-8CD5-4FBF-9DC4-1 837DD2691 89
3.3. Data Collection Format
Contractor shall provide the required reports via Managed File Transfer (MFT).
3.3.1. HCA anticipates shifting the data collection format at least in part from MFT to the
Program Data Acquisition Management and Storage (PDAMS) system prior to the
end date of this Contract.
3.3.1.1 . Contractor shall continue to collect data via MFT method until notified
otherwise by the HCA Contract Manager in writing.
3.3.1.2. HCA Contract Manager shall notify Contractor of this change no less
than ten (10) Business Days before implementing the new collection
format.
4. COST REIMBURSEMENT
The payment format for this Contract is established as cost reimbursement. Reports and receipts
must be submitted monthly with each A-19 invoice, as identified in this section and in Contract
Section 3.4, lnvoice and Payment.
4.',. Allowable Expenses
Only purchases and staff time which are not part of a Medicaid billable service are allowable.
Refer to the following documents for Medicaid billing guidance and fee schedules.
4.1.1. Reentrv from a carceral settinq I Washinqton State Health Care Authoritv
4.1.2. Reentrv lnitiative Policv and Operations Guide
4.1.3. Provider billinq quides and fee schedules I Washinqton State Health Care Authoritv
4.1.4. Email questions to hcareentrvdemonstrationproiect@hca.wa.oov.
4.2. Monthly Estimated Costs
The estimated monthly cost reimbursement is as follows:
4.2.1. July 1 ,2025 - June 30,2026
$17,416
Monthly Estimated Cost
1 2
Number of Months
$209,000
TotalCosts
4.2.2.
4.2.3
Adjustments revising twenty-five percent (25%) or more of the Monthly Estimated
Costs as identified in this section 4.2 must be submitted to the HCA Contract
Manager or designee for approval in writing, via email, at least fifteen (15) Business
Days prior to expending the adjusted funds.
HCA approval must be granted, in writing, prior to expending funds.
4.3. lnvoicing
lnvoices must be submitted in conjunction with the monthly reports identified in Section 3,
Reporting, and as follows:
HCA Contract No. K5885-04 Page 9 of 13
Docusign Envelope lD: 97E7029C-SCDHFBF-9DC4-1 837DD2691 89
4.3.1.
4.3.2.
lnvoices shall be due no later than the 10s day of the month following the month in
which the expenses being invoiced were expended; and
As outlined in Contract Section 3.4, lnvoice and Payment.
HCA Contract No. K5885-04 Page 10 of 13
Docusign Envelope lD: 97E7029C-8CD5-4FBF-9DC4-1837DD269189
ATTACHMENT 1
MOUD & MAUD in Jails Program Monthly Progress Report
Please give a sentence or two in response to each prompt below. These are not yes or no questions
but rather guidance on what is needed for program compliance. lt is important to share that funding is
being spent in accordance with program requirements, that the funding is needed, and that the
program is successful.
Please plan to discuss your program and bring innovative ideas to each monthly HCA partner
meeting.
1, Key information
Gontract Funding End:
Contract Funding Start:
Project Manager(s):
Month Reporting on:
Gontractor Name:
June 30, 2026
July 1,2025
2. How are funds spent for this program?
This section may be the same each month.
2.1. Staff:
2.2. Medications:
2.3. Subcontractors:
2.4. Naloxone:
2.5. Release Kits:
2.6. Other:
3. Narrative Progress Report
lnclude meeting the standard of care, barriers, solutions, Training and Technical Assistance
(TTA), successes, who is providing each step, what tools are being used, etc.
3.1. Screening or assessments for OUD and AUD and for risk of acute withdrawal.
3.2. How are withdrawals being treated?
3.3. Continuing or inducing MOUD or MAUD.
3.4. Release plan and reentry coordination, including:
3.4.1. Schedule first community follow-up appointment; and
3.4.2. Bridge medication upon release.
4. Successes
lncluding program or individual participant successes
5. Ghallenges
lnclude both challenges faced and what solutions are being considered
HCA Contract No. K5885-04 Page 11 of 13
Docusign Envelope lD: 97E7029C-8CD5-4FBF-9DC4-1 837DD269189
6. How many individuals were screened for alcohol use disorder?
7. How many individuals began, or were continued on, Medications for Alcohol Use Disorder
(MAUD)?
8. Which MAUDs are being offered and which one is being chosen the most often?
HCA Contract No. K5885-04 Page 12 of 13
Docusign Envelope lD: 97E7029C-8CD5-4FBF-9DC4-1 837DD269'1 89
ATTACHMENT 2
MOUD Monthly Data Collection Spreadsheet
The current Contract Attachment 2, MOIJD Monthly Data Collection Spreadsheef, including any and all
modifications, is incorporated herein by reference. Any questions regarding the use or purpose of this
form may be submitted to the HCA Contract Manager.
HCA Contract No. K5885-04 Page 13 of 13